about
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersResistant HypertensionThrombocytopenia in pregnancy - pathogenesis and diagnostic approachDisseminated nocardiosis as a complication of Evans' syndrome.Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factorEffect of Regular Aerobic Activity in Young Healthy Athletes on Profile of Endothelial Function and Platelet Activity.IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemiaLeft ventricular diastolic dysfunction and plasma asymmetric dimethylarginine concentration in persons with essential hypertensionLow expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients.Psychometric evaluation of the Polish adaptation of the Hill-Bone Compliance to High Blood Pressure Therapy ScaleEffect of the transdermal low-level laser therapy on endothelial function.Elevated plasma ADMA contributes to development of endothelial dysfunction in children with acute lymphoblastic leukemia.Endothelial Function in Patients with Hematologic Malignancies Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation.High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients.Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemiaHigh density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend?Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.Relationship between patients' knowledge and medication adherence among patients with hypertension.Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.Selected factors affecting adherence in the pharmacological treatment of arterial hypertension.Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes.Sociodemographic and Clinical Determinants of Quality of Life of Patients with Non-small Cell Lung Cancer.Identification of miRSNPs associated with the risk of multiple myeloma.Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia.The relationship between selected VDR, HFE and ALAD gene polymorphisms and several basic toxicological parameters among persons occupationally exposed to lead.VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma.Cognitive deficits and self-care behaviors in elderly adults with heart failure.Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.The CXCL12-3'A allele plays a favourable role in patients with multiple myeloma.Role of the functional MNS16A VNTR-243 variant of the human telomerase reverse transcriptase gene in progression and response to therapy of patients with non-Hodgkin's B-cell lymphomas.Heart rate variability and heart rate turbulence in patients with hematologic malignancies subjected to high-dose chemotherapy in the course of hematopoietic stem cell transplantation.Unclassifiable small B-cell lymphoma with marked plasmacytic differentiation and Mott cell formation.Asymmetric dimethylarginine in hematological malignancies: a preliminary study.Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma.Breast cancer and synchronous multiple myeloma as a diagnostic challenge: Case report and review of literature.Role of the Lymphatic System in the Pathogenesis of Hypertension in Humans.Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).Low-Level Laser Irradiation Exerts Antiaggregative Effect on Human Platelets Independently on the Nitric Oxide Metabolism and Release of Platelet Activation Markers.
P50
Q26740443-9EA66B34-5BC6-4FF9-BEEE-58E939F5FC28Q26764991-6C17D7DF-9046-4874-B611-997E67C9EA23Q26777371-0D4B943C-95F3-4381-B186-FDE46B436452Q33329829-E011130B-3C66-43F0-A4CA-BFF0B6094573Q33424228-263DCD3B-6DEA-4AE8-BB3E-741076FC4C18Q33654957-DEA4F102-CCFA-4FE3-8E3D-27B39D9185CBQ33786736-7E26571E-BD74-4804-B347-33C13940D1CFQ34038176-24FF7795-6894-420E-A09E-F75B44DBF6F4Q35829220-E068C8A6-63EF-4F6F-B940-798C1223AD66Q35869716-A5AD2FF9-7F22-4DF4-B2C5-55F92266B26FQ36013903-9CF7FD81-EC14-418C-A531-4A17DF677D57Q36051544-6C8A2C3C-86C6-48EC-9D83-B9F5B0B1F50EQ36059187-F79CDF19-1989-4A6E-8D1F-314DAE904CDEQ36678516-1AB55D85-82F4-4B25-809C-97BF15C87B0DQ36886172-404206F0-BCDC-48C8-9337-94F1B91C0C28Q37288474-0B654EFF-44D7-4A4D-AF2C-7581A4672AAFQ37298544-8F429272-FD5E-44CD-8B2E-FBAF9EC16AAEQ37327466-B37A787C-B06C-4B2B-8710-B9200DFE635AQ37496556-FEF1E61F-94A4-4425-A344-52BD7D9EA5D7Q37677977-44AE4DA8-389F-45B3-8C1A-31E046762142Q37682872-DC2E0ACD-CC45-4BB2-827E-E0D12E059014Q38397004-B6F8BF93-62FA-4EF0-8D5E-DE3EC62E58B3Q38740856-C64D7647-8D17-494F-BE98-17E464E0BE87Q38749568-D7B281F4-950B-481C-B665-01E27F8BD4E5Q39309897-C080CB69-1287-4E48-A3F7-151973347D20Q39770651-FBB93B55-9E50-4971-A02E-D9D77F961FF4Q40950768-51D663EC-C363-4908-9E3E-387B87F472A7Q41953798-AD175794-7606-478A-BA52-83B70A15CED2Q42373171-18DD8E69-6A28-44A0-8164-49D74AACE07EQ43296842-06A80902-8AE2-4A90-A118-6AF3E119E9E9Q43432704-8DE29FA0-3A76-492D-A1CC-FD591D0ABA99Q44058153-05EF3D2F-BB37-4B1C-AF35-16C1B096066BQ45754683-F33AF7C1-7D06-40EB-8E9D-F464AAB6F342Q45945456-633E1AD8-1322-4DA5-8721-B460B27FF7ACQ46216898-0BF68B3F-54F3-4FC7-9EE2-B915EB5ABD0DQ46803935-F18A2C9C-D634-4C40-B5C6-10EC7F6F60AAQ47292911-EA76C7DE-AC0B-4820-8CC5-CD724973A136Q47561234-5A6D5079-4A03-42B2-9D2D-79A41CC2EED1Q47580836-85EE0486-2201-40E7-834D-61CA2A51F6C4Q47639600-09631FA0-532D-41BD-8ADE-B360DC55A491
P50
description
researcher
@en
name
G Mazur
@en
G Mazur
@nl
type
label
G Mazur
@en
G Mazur
@nl
prefLabel
G Mazur
@en
G Mazur
@nl
P106
P31
P496
0000-0001-6610-2008